雌激素受体PET显像用于妇科肿瘤
本文综述了18F-FES PET在雌激素依赖性妇科肿瘤(如子宫内膜癌、平滑肌瘤等)表型分析中的应用,展示了其相对于18F-FDG PET在诊断与预后判断中的附加价值,并介绍了其他有前景的PET示踪剂。18F-FES PET已在雌激素受体阳性乳腺癌的诊断、分期和治疗后随访中确立地位。
要点
- 18F-FDG PET在妇科恶性肿瘤转移灶和局部复发的检出及疗效评估上优于常规影像。
- 18F-FES是雌二醇的18F标记化合物,18F-FES PET已用于雌激素受体阳性乳腺癌的诊断、分期和治疗后随访。
- 本文综述18F-FES PET对非乳腺癌的雌激素相关妇科肿瘤的表型分析及其附加价值。
核心结论
- 18F-FES PET可用于雌激素相关妇科肿瘤的表型分析,并较18F-FDG PET在诊断和预后判断中具有附加价值。
研究设计与样本
- 本文为综述,回顾了18F-FDG PET在妇科恶性肿瘤中的应用及18F-FES PET在雌激素相关妇科肿瘤中的研究进展。
主要发现
- 18F-FDG PET在检测妇科恶性肿瘤转移灶和局部复发以及评估治疗反应方面,诊断准确性优于常规影像方法。
- 与肿瘤活检材料的体外评估相比,PET显像可测量体内肿瘤行为、刻画整个肿瘤负荷并捕捉肿瘤表型的异质性。
- 18F-FES PET已在雌激素受体阳性乳腺癌患者的诊断、分期和治疗后随访中确立。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the past few decades, PET with 18F-FDG has been used for the diagnosis of gynecological malignancies and is considered to be superior to conventional imaging methods in diagnostic accuracy for detecting metastatic lesions and local recurrence and in evaluating the treatment response. On the other hand, several gynecological tumors, such as endometrial cancer and leiomyoma, and breast cancer are estrogen-dependent, in which estrogen is essential for their development and progression. 18F-FES is an 18F-labeled compound of estradiol, the most bioactive type of estrogen, and 18F-FES PET has been well-established for diagnosis, staging, and posttherapeutic follow-up in patients with estrogen receptor-positive breast cancer. Compared with in vitro assessment of tumor biopsy material, PET imaging has the advantages of being able to measure in vivo tumor behavior, characterize the entire tumor burden, and capture the heterogeneity of the tumor phenotype. In this article, we review the phenotyping of estrogen-related gynecological tumors other than breast cancer using 18F-FES PET and demonstrate the additional value of 18F-FES PET to 18F-FDG PET in their diagnosis and prognostication. Moreover, promising PET tracers other than 18F-FES and 18F-FDG for the evaluation of estrogen-related gynecological tumors are introduced.
引用
- Tsujikawa T, Makino A, Mori T, et al. PET Imaging of Estrogen Receptors for Gynecological Tumors. Clin Nucl Med. 2022. PMID: 35675139. doi:10.1097/RLU.0000000000004258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。